Streptococcus Salivarius M18: A Probiotic for Oral Health

Streptococcus salivarius M18 is a probiotic bacterium originally isolated from the mouth of a healthy adult, selected specifically because it produces antimicrobial compounds and enzymes that target the bacteria responsible for cavities and gum disease.¹ Unlike gut-focused probiotics you swallow in capsules, M18 is designed to colonize the mouth itself, typically delivered as a slow-dissolving lozenge or chewable tablet. The clinical evidence for it is still relatively young, but several randomized trials point to real benefits for plaque, gingival bleeding, and cavity-causing bacteria, with some significant caveats about how well it colonizes and how long results last.

How M18 Fights Oral Pathogens

M18 works through a few distinct mechanisms rather than a single trick. The most studied is its production of bacteriocins, which are small antimicrobial proteins that specifically target Streptococcus mutans, the bacterium most closely linked to tooth decay.² Think of these as tiny, highly selective weapons: they punch holes in the membranes of S. mutans cells while leaving most other oral bacteria unharmed. The genome of M18 has been sequenced and confirms the genetic machinery for producing these bacteriocins.³

M18 also produces two enzymes that matter for oral health. Dextranase breaks down dextran, a sticky sugar polymer that S. mutans uses to glue itself to tooth surfaces and build up plaque. By degrading this glue, M18 can help disrupt plaque formation. The second enzyme, urease, breaks down urea naturally present in saliva and converts it into ammonia, which raises the local pH. This is significant because the acid produced by cavity-causing bacteria is what actually dissolves tooth enamel. By neutralizing that acid, urease activity can protect teeth even when harmful bacteria are still present.⁴ A review of probiotic mechanisms in caries prevention confirmed that this combination of pH buffering, bacteriocin production, and enzyme activity represents the main ways oral probiotics deliver their effects.⁵

What the Cavity Prevention Trials Show

The most consistent clinical finding for M18 is a reduction in salivary counts of S. mutans, particularly in children. In a randomized trial of preprimary children, those given M18 showed a significant drop in salivary S. mutans levels, while children receiving a placebo saw a slight, nonsignificant increase.⁶ An earlier double-blind trial in children similarly found that a subgroup of children who were effectively colonized by M18 exhibited reduced S. mutans counts, suggesting that the probiotic’s anti-cavity activity depends on how well it takes hold in a given person’s mouth.²

A separate randomized controlled study went further and used the Cariogram model, a risk-assessment tool that estimates the probability of developing new cavities. After 90 days of M18 supplementation, children at high caries risk showed improved Cariogram scores, meaning their estimated chances of avoiding new cavities had gone up. The researchers concluded that M18 could serve as an additional tool for dentists managing high-risk patients.⁷

An important thread runs through all these trials: the effects are modest and appear strongest in children who already have high cavity risk. M18 is not a replacement for brushing, flossing, or fluoride. It looks more like a useful add-on for people whose existing hygiene routine is not enough to keep S. mutans in check.

Gum Disease and Bleeding

M18’s benefits are not limited to cavities. Two recent randomized trials examined its effects on gingival (gum) health, and both found measurable improvements. In a three-month supplementation study, people receiving M18 lozenges experienced a significant decrease in gingival bleeding starting as early as one month into treatment, with the effect persisting through the full three months. Plaque accumulation also dropped significantly by the second month.⁸ Participants on the placebo saw no change in either measure.

A trial focusing specifically on periodontitis patients found even more striking results. Used alongside standard periodontal treatment (scaling and root planing), M18 significantly reduced probing pocket depth, bleeding on probing, and plaque index scores compared to placebo. These reductions were sustained at the immediate follow-up assessment. Bleeding reductions remained significant at two months post-treatment, and plaque reductions were also significant at that time point.⁹ However, no significant difference in clinical attachment loss, a measure of how much the gum has actually receded from the tooth, was observed between the two groups at any time point. This suggests M18 helps reduce inflammation and bacterial burden but may not reverse the structural damage that advanced gum disease has already caused.

How M18 Dampens Gum Inflammation

Part of the mechanism behind those gum health improvements appears to be immune modulation rather than just killing bacteria. In lab experiments using human gingival fibroblasts (the cells that make up gum tissue), M18 did not trigger an inflammatory response on its own. But when it was present alongside periodontal pathogens, it significantly reduced the release of the inflammatory signaling molecules IL-6 and IL-8. This dampening effect held whether M18 was introduced at the same time as the pathogen or used to pre-treat the gum cells beforehand.¹⁰ In other words, M18 appears to calm down the gum tissue’s alarm response to harmful bacteria without suppressing the immune system more broadly. This is a meaningful distinction: chronic gum disease is driven as much by the body’s own inflammatory overreaction as by the bacteria themselves.

Effects on Bad Breath

Bad breath (halitosis) is largely caused by volatile sulfur compounds, particularly hydrogen sulfide and methyl mercaptan, produced by anaerobic bacteria in the mouth. M18 has shown a clear ability to suppress these compounds in laboratory settings. When M18 was co-cultured with common halitosis-causing bacteria like Porphyromonas gingivalis and Treponema denticola, the levels of volatile sulfur compounds dropped significantly as the concentration of M18 increased.¹¹

A more detailed in-vitro study tested M18 against a broader panel of six pathogenic species and confirmed the pattern. Both hydrogen sulfide and methyl mercaptan concentrations decreased across all tested ratios of M18 to pathogenic bacteria. The study also found that M18 reduced the expression of a virulence-related gene in P. gingivalis, which may limit that pathogen’s ability to break down tissue proteins that fuel sulfur compound production.¹² The catch is that this evidence is entirely from lab experiments, not from clinical trials measuring actual breath quality in people. The biological plausibility is strong, but controlled human studies on halitosis specifically have not been published for M18.

Does M18 Actually Colonize Your Mouth?

This is where the story gets more complicated. For M18 to work, it needs to stick around in the oral cavity long enough to produce its antimicrobial compounds. A persistence study in 75 subjects receiving different doses over 28 days found that colonization was dose-dependent: higher doses led to more consistent detection of M18 in saliva afterward. In some individuals, M18 nearly completely replaced their existing S. salivarius populations, although the total numbers of the species did not increase beyond normal levels.¹³ This is encouraging: it means M18 can integrate into the existing microbial community rather than simply ballooning the total bacterial population.

However, not everyone colonizes equally well, and the duration of supplementation did not seem to matter as much as the dose. More importantly, the three-month gum health trial noted that benefits did not persist after supplementation stopped, suggesting that continuous use may be necessary for sustained effects.⁸ This fits a broader pattern with oral probiotics: they are more like a daily supplement than a one-time fix. Once you stop taking them, the introduced strain gradually gets outcompeted by whatever was already living in your mouth.

When M18 Does Not Work As Hoped

Not every trial has produced positive results. A small pilot study in head and neck cancer patients who had undergone radiation therapy tested M18 lozenges over four weeks. While plaque scores improved in both the probiotic and placebo groups, there was no significant difference between the two. The probiotic did not significantly change overall bacterial community composition or diversity, and it did not increase the detectable levels of S. salivarius in plaque samples, suggesting the probiotic could not penetrate the existing biofilm.¹⁴

This study was tiny (only 13 patients total) and involved a population with severely disrupted oral environments from radiation. So it does not invalidate the broader evidence. But it does illustrate a real limitation: M18 may struggle in mouths where the microbial ecosystem has been radically altered by medical treatment, or where thick, established biofilms resist new colonizers. The finding that M18 could not penetrate existing plaque biofilm is particularly worth noting, because it suggests the probiotic works best when used alongside mechanical cleaning (brushing, professional scaling) that disrupts those biofilms first.

M18 Versus K12

If you have looked into oral probiotics before, you have probably encountered Streptococcus salivarius K12, a related strain developed primarily for throat and upper respiratory health. M18 and K12 are siblings in the same species, but they are optimized for different niches. K12 is better studied for sore throats, ear infections, and pharyngeal health. M18 is formulated specifically for the teeth and gums.

That said, the two strains share some abilities. Both suppress the growth of the same panel of oral pathogens, including P. gingivalis, F. nucleatum, and T. denticola, and both reduce volatile sulfur compound production at comparable rates in lab settings.¹² Both also dampen gum tissue inflammation when co-administered with periodontal pathogens.¹⁰ Some commercial products combine both strains in a single lozenge, though there is limited clinical data specifically studying the combination versus either strain alone.

Safety Profile

S. salivarius is one of the first bacteria to colonize a human mouth after birth, so M18 is not introducing a foreign organism. It was isolated from a healthy adult and evaluated specifically for safety in probiotic applications.¹ Genomic analyses of S. salivarius probiotic strains have confirmed the absence of antibiotic resistance genes, virulence factors, and mobile genetic elements that could transfer resistance to other bacteria.¹⁵ No serious adverse events have been reported in any of the published clinical trials. The persistence data mentioned earlier also shows that M18 does not cause total S. salivarius levels to spike beyond normal ranges, which is reassuring from an ecological standpoint.

The main practical caution is for people who are severely immunocompromised. While healthy individuals tolerate M18 without issue, introducing any live bacteria in someone with a deeply suppressed immune system warrants discussion with a doctor. This applies to oral probiotics generally, not to M18 specifically.

The Commercial Product Problem

Even if M18 itself is well-supported, the product you buy off the shelf may not deliver what you expect. A study that analyzed 21 commercially available oral probiotic products found that many failed to contain the claimed number of viable cells. Worse, some products used strains that were inadequately characterized and lacked clinical evidence for that specific strain, making the “probiotic” label questionable.¹⁶ The study also found that lyophilized (freeze-dried) probiotics, which is how nearly all commercial products are formulated, demonstrated low adhesive capacity compared to fresh bacteria. This raises a fundamental question about whether the delivery format most people encounter actually lets the probiotic do its job.

If you are considering an M18 product, look for one that specifies the strain (not just the species), lists a guaranteed colony-forming unit count at expiration (not at time of manufacture), and ideally references a specific clinical trial. Products that vaguely claim “contains S. salivarius” without naming the M18 strain are not necessarily using the clinically studied organism.

Black Stains in Children

One niche application that has drawn research attention is the use of M18 for black stain, a form of dental discoloration common in children. Black stain is caused by chromogenic bacteria, particularly certain iron-sulfide-producing species, and tends to recur even after professional cleaning. A study investigated whether M18 supplementation could prevent the reappearance of black stains after professional removal, assessing children at three and six months post-cleaning.¹⁷ The rationale is straightforward: if M18 can shift the oral bacterial community away from chromogenic species, the stains might take longer to return or not return at all. The research on this question is still early, and it represents one of the more speculative applications for the strain, but it illustrates how the probiotic’s broad antimicrobial activity might be useful beyond the standard targets of cavities and gum disease.